ENO1 and breast cancer: Certain scholars have reported that the complement C5a receptor 1 (C5AR1)+/WTAP/enolase 1 (ENO1) axis regulates the glycolytic activity of BC cells and the lncRNA DLG-associated protein 1-antisense 1/miR-299-3p/WTAP axis promotes the proliferation of drug-resistant BC cells, which is worthy of further exploration (118,119).